| Print
Regencell Bioscience Holdings Limited (RGC)
Ordinary SharesThis share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Company profile
Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.
Address
Forecast key dates
| Name | Key Date |
|---|---|
| Regencell Bioscience Holdings Ltd Annual Report for 2026 | 2026-10-30T00:00:00 |
| Regencell Bioscience Holdings Ltd Second Quarter Earnings Results for 2026 | 2026-02-16T00:00:00 |
| Regencell Bioscience Holdings Ltd Annual General Meeting for 2024 | 2026-02-10T00:00:00 |
Previous key dates
| Name | Key Date |
|---|---|
| Regencell Bioscience Holdings Ltd Second Quarter Earnings Results for 2026 | 2026-02-16T00:00:00 |
| Regencell Bioscience Holdings Ltd Annual General Meeting for 2024 | 2026-02-10T00:00:00 |
| Regencell Bioscience Holdings Ltd Annual Report for 2025 | 2025-10-31T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.